OptiBiotix Health PLC

24 October 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

Approval of GoFigure products with Saudi Food and Drug Authority

OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d eveloping compounds to tackle obesity, cardiovascular disease and diabetes , announces its exclusive distributor Nahdi Medical Co ("Nahdi") has received approval from the Saudi Food and Drug authority (" SFDA") for GoFigure shakes and bars containing patented weight management aid SlimBiome(R).

The Company announced it had signed an exclusive sales and marketing agreement with Nahdi in December 2021. Nahdi owns the largest pharmacy network in the Kingdom of Saudi Arabia ("KSA") with over 1,100 pharmacy outlets countrywide. Nahdi's online platform, Nahdi Online, is one of the leading e-commerce pharmacy players across the six countries of the Gulf Cooperation Council ("GCC") https://www.nahdionline.com/en/ .

The SFDA approval originally envisaged for early 2022, is a critical milestone on the way to marketing and selling the GoFigure range of products through the pharmacies of Nahdi in Saudi Arabia. The SFDA approval is of strategic importance to both Nahdi and OptiBiotix as it facilitates the registration processes in the other GCC countries ( Bahrain , Kuwait , Oman , Qatar and the United Arab Emirates ) .

As a direct consequence, OptiBiotix has received the first purchase order from Nahdi. The manufacturing of the range of products has commenced and the launch envisaged for Q1 2023 is in full preparation. The initial launch is planned to take place in strategically key locations within Saudi Arabia and through Nahdi's e-commerce platform.

GoFigure is OptiBiotix' direct-to-consumer (D2C) range of weight management products formulated with core ingredient SlimBiome(R). The GoFigure range of products consists of powdered meal replacement & beverage products (shakes, smoothies, pancake mixes, etc) and healthy snacking (crisps, puffs, gummies, etc.).

SlimBiome(R) is a patented prebiotic weight management aid used as such or in formulated products in the health & wellness, sports nutrition and weight management categories. SlimBiome (R) is supported by independent human clinical studies which show it reduces hunger, cravings for sweet and savoury foods and fat intake, and helps people stick to a low calorie diet plan. Consumers who used SlimBiome (R) in combination with a calorie restricted diet experience a relief from feeling hungry and have fewer cravings for food, leading to easier and more sustainable dieting and lose on average an additional 2kg of fat per month, improving body composition.

René Kamminga, C EO of O pti B i oti x Limited, a wholly owned subsidiary of OptiBiotix Health plc, c o m mented: "I am very pleased the regulatory approval process is now complete and that we can now focus on getting the GoFigure range direct to the Saudi consumer. The GoFigure range has been specifically formulated to support consumers aiming to reduce their weight, help them stick to their change in diet and improve their gut microbiome at the same time. This particular range has been adapted specifically to fit the consumer preferences in Saudi Arabia and we are confident that we can build lasting success with our partner Nahdi."

For further information, please contact:

 OptiBiotix Health plc                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive             Contact via Walbrook below 
 Walbrook PR Ltd                                     Mob: 07876 741 001 
 Anna Dunphy 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

October 24, 2022 02:00 ET (06:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Gen 2023 a Feb 2023 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Feb 2022 a Feb 2023 Clicca qui per i Grafici di Optibiotix Health